When do Sodium Picosulfate, Magnesium Oxide And Anhydrous Citric Acid patents expire, and what generic alternatives are available?
Sodium Picosulfate, Magnesium Oxide And Anhydrous Citric Acid is a drug marketed by Hetero Labs Ltd V and is included in one NDA.
The generic ingredient in SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID is citric acid; magnesium oxide; sodium picosulfate. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.
AI Deep Research
Questions you can ask:
What is the 5 year forecast for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID?
What are the global sales for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID?
What is Average Wholesale Price for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID?
Summary for SODIUM PICOSULFATE, MAGNESIUM OXIDE AND ANHYDROUS CITRIC ACID
Market Dynamics and Financial Trajectory for Sodium Picosulfate, Magnesium Oxide, and Anhydrous Citric Acid
Last updated: February 24, 2026
What Are These Ingredients Used For?
These compounds are primarily active or excipient components in bowel preparation formulations. Sodium picosulfate acts as a stimulant laxative, magnesium oxide is an osmotic laxative and antacid, and anhydrous citric acid serves as a pH modifier and flavor enhancer.
Market Overview and Key Drivers
The global market for bowel preparation drugs is expanding. The compound-specific insights include:
Sodium Picosulfate: The dominant active ingredient in OTC laxatives and prescription bowel prep drugs. Sales are driven by increasing colorectal cancer screening due to higher colorectal cancer incidence and aging populations.
Magnesium Oxide: Used in antacid formulations and bowel prep solutions. Its demand correlates with gastrointestinal disorder prevalence and OTC supplement trends.
Anhydrous Citric Acid: A common excipient with demand linked to its use in pharmaceuticals, food, and beverages, including bowel prep formulations.
Market Size and Growth
Global Market Valuation (2022-2026)
Segment
2022 Market Value (USD billion)
Compound Annual Growth Rate (CAGR) (2022-2026)
Sodium Picosulfate products
2.1
4.8%
Magnesium Oxide formulations
1.2
3.5%
Anhydrous Citric Acid applications
0.8
4.2%
Source: Research & Markets (2022)[1]
Regional Insights
North America: Largest market share, driven by high prevalence of colorectal cancer screening and OTC laxative use.
Europe: Significant growth, influenced by aging populations and regulatory approvals for bowel prep drugs.
Asia Pacific: Fastest CAGR, supported by increasing healthcare access and rising gastrointestinal disorders.
Supply Chain and Manufacturing Trends
Raw Material Availability: Globally widespread, with significant production in China and India.
Manufacturing Consolidation: Companies are integrating vertically to control raw material supply chains.
Regulatory Impact: Stringent regulations influence manufacturing practices, especially in North America and Europe.
Competitive Landscape
Major Players: Bayer, Sanofi, Ferring Pharmaceuticals, and local generic manufacturers.
Strategic Initiatives: Focus on product innovation, regulatory approvals, and expanding manufacturing capacity.
Pricing and Revenue Projections
The average price for bowel prep products containing these ingredients has increased by approximately 2.5% annually over the past three years.
The projected revenue for products incorporating sodium picosulfate is expected to reach USD 3.5 billion globally by 2026, up from USD 2.1 billion in 2022.
R&D and Innovation Trends
Formulation Improvements: Development of low-volume, electrolyte-balanced solutions to enhance patient compliance.
Alternative Ingredients: Exploration of emerging laxatives and excipients to replace existing compounds amid patent expiries.
Regulatory Approvals: New formulations with improved safety profiles are pending approval in emerging markets.
Regulatory Considerations
Sodium picosulfate has been approved by the FDA and EMA for bowel prep uses.
Manufacturing standards are governed by Good Manufacturing Practices (GMP), with increasing emphasis on quality assurance.
Patent expiries for certain formulations could lead to generic competition and price erosion.
Investment and Partnership Opportunities
Growing demand in Asia Pacific creates opportunities for manufacturing scale-up.
Strategic collaborations for R&D focused on safer, more effective bowel prep solutions.
Entry into emerging markets via acquisitions or joint ventures.
Risks to Market Growth
Regulatory delays could hinder new product approvals.
Price competition among generic manufacturers may reduce profit margins.
Potential safety concerns or adverse event reports could impact demand.
Key Takeaways
The market for bowel preparation drugs incorporating sodium picosulfate, magnesium oxide, and anhydrous citric acid is expanding at a CAGR of approximately 4-5%, driven by aging populations, screening programs, and OTC demand.
Regulatory landscape and patent expiries influence market competitiveness and pricing.
Regional differences present both challenges and opportunities, especially in the Asia Pacific market.
Innovation focused on safety, efficacy, and patient compliance remains a strategic priority.
Manufacturers should monitor raw material supply chains, regulatory shifts, and competitive moves.
FAQs
What is the primary therapeutic application for sodium picosulfate?
It is used as a stimulant laxative in bowel preparation solutions and OTC laxatives.
How does magnesium oxide contribute to bowel prep formulations?
It acts as an osmotic laxative and antacid, aiding bowel evacuation and reducing acidity.
What factors are driving demand in the Asia Pacific region?
Increasing healthcare access, dietary lifestyle changes, and rising gastrointestinal disorders.
Are there safety concerns associated with these compounds?
Excessive intake of magnesium oxide can cause electrolyte imbalances; regulatory bodies monitor safety profiles closely.
What are the main opportunities for new entrants?
Entry points include manufacturing scale in emerging markets, innovation in formulation, and strategic alliances for R&D.
References
[1] Research & Markets. (2022). Global Market for Laxatives and Bowel Preparation Drugs. Retrieved from https://www.researchandmarkets.com
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
